A Practice Note addressing disclosure requirements for group health plans and health insurers that were part of federal spending legislation enacted in December 2020 in response to COVID-19 (the disease that results from SARS-CoV-2). This resource also addresses a CAA-21 reporting requirement involving pharmacy benefits and prescription drug costs.